Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients.
about
Interleukin 2 receptor antagonists for kidney transplant recipientsA Proposal for Early Dosing Regimens in Heart Transplant Patients Receiving Thymoglobulin and Calcineurin InhibitionThe Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant RecipientsNew directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunityDelayed graft function in the kidney transplantInduction immunosuppressive therapy in the elderly kidney transplant recipient in the United StatesLong-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants.Use of monoclonal antibodies in renal transplantation.Polyclonal antithymocyte globulin and cardiovascular disease in kidney transplant recipientsProlonged CD4 T cell lymphopenia increases morbidity and mortality after renal transplantation.Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipientsDiagnosis and management of antibody-mediated rejection: current status and novel approaches.A comprehensive and quantitative analysis of the major specificities in rabbit antithymocyte globulin preparations.Poor outcomes in elderly kidney transplant recipients receiving alemtuzumab induction.New-onset diabetes after renal transplantation: risk assessment and management.PREventing Delayed Graft Function by Driving Immunosuppressive InduCtion Treatment (PREDICT-DGF): study protocol for a randomized controlled trialHIV-infected kidney graft recipients managed with an early corticosteroid withdrawal protocol: clinical outcomes and messenger RNA profiles.Genome-Wide Association Study of Acute Renal Graft Rejection.Induction Therapy for Kidney Transplant Recipients: Do We Still Need Anti-IL2 Receptor Monoclonal Antibodies?Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy.Risk factors and outcomes of delayed graft function in renal transplant recipients receiving a steroid sparing immunosuppression protocol.Antibody immunosuppressive therapy in solid-organ transplant: Part I.Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation.Current landscape for T-cell targeting in autoimmunity and transplantation.Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation.Induction therapy in renal transplant recipients: how convincing is the current evidence?The role of Thymoglobulin induction in kidney transplantation: an update.Pretransplant identification of acute rejection risk following kidney transplantation.Cytolytic Induction Therapy Improves Clinical Outcomes in African-American Kidney Transplant Recipients.Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant.Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation: a health economic analysis from a German perspective.Effectiveness of an Evidence-Based Induction Therapy Protocol Revision in Adult Kidney Transplant Recipients.Co-stimulation Blockade Plus T-Cell Depletion in Transplant Patients: Towards a Steroid- and Calcineurin Inhibitor-Free Future?Prediction, prevention, and management of delayed graft function: where are we now?Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects.Delayed graft function and its management in children.A comparison of three induction therapies on patients with delayed graft function after kidney transplantation.Efficacy and safety of antibody induction therapy in the current era of kidney transplantation.Kidney transplant after hematopoietic cell transplant in pediatrics: Infectious and immunosuppressive considerations.Heterogeneity of induction therapy in Spain: changing patterns according to year, centre, indications and results
P2860
Q24240492-02DD0AD2-2762-464B-AB0E-2D765272F712Q26738510-F8BAC458-6082-43A5-9A00-72605C4D6B0DQ26774993-A20E05D5-E776-4123-9913-DE3B58844209Q26823090-6B20ABC3-DFCE-4241-8E5D-052C4F0BA4E7Q26824506-4E84FD10-67B7-442A-9CED-05C606D4DD24Q28740458-08268406-6DD8-477C-A99D-15CE4409F45FQ30987986-FFACE6BC-FB16-4EFC-A093-2C80DEBC0501Q33396236-12EE94C9-3469-492E-9993-0178BDCCE6F1Q33660602-D7B5966A-27F2-4B9F-A801-C52037C3E50DQ33834302-D1B88E3F-5B99-484F-B93C-6BF61B1D3431Q33930084-8FE1E11E-D040-4D0D-A57B-B18DFEC685D8Q34841849-1128D758-4A96-446F-A998-61B9912D9BD6Q35028105-ED8EE700-82BF-40E6-93D7-E097688BAC16Q35611179-BF58A2D2-94FD-4376-980B-A163AE6CE043Q35620221-8D490510-A07A-4920-8097-0588EDA35909Q35770443-E5D8FC06-8013-437E-8F7F-FF2F9C25A3B4Q36818017-D1AA4C11-C237-4346-8336-883F684AD917Q37560649-BCE4BD6F-69D5-4AB0-A1B8-8DF93E3BD4E1Q37561282-D3F5DD29-E261-490F-A218-1B6B037F42FCQ37660263-A0699EB5-FAD1-4BE2-8C58-9B40AB9B9B56Q37662995-359BFE75-9318-451B-9B35-00F8D06FF74AQ37691180-D2C47EBB-F728-4B6C-83A7-CED34A5A021AQ37736501-0D1C0C45-2614-4D82-B15E-B831672B0CA0Q37900647-64951F57-EE0D-4659-BA89-F363256FCA40Q37939057-0C7F541D-65AA-4251-B9CF-2B1798E17866Q37996078-2EE0BE55-AAE6-4C0F-B618-76409C86AC5BQ38051718-2B4389FA-8D12-4E04-A648-8EA0515CE6A2Q38151922-B2CC05F0-F351-4134-919F-4D7B3A4FF6AEQ38706959-7A912C10-B27B-4E99-963A-8BEAFDB24610Q38731333-60942F1D-F6EE-471C-99A3-87645439A79DQ38757281-5916E817-5996-4533-B3A6-2468799D284EQ38802439-2CD8C3A8-A018-4652-A0B3-EE1EDE031F9CQ38804454-28008903-C2D8-42D7-A023-21A935179E43Q38829547-E1592468-7790-49CA-971C-53497FC781AAQ38995172-DC354528-F54F-4678-B739-BC94F87EFB74Q39252265-6499F6BD-7626-423B-AF1F-F0679A9EE1D3Q39541551-7F971A5F-FDA3-499E-AEE7-8DB0450E89E3Q39757976-FF62A0CD-55B3-4D73-B613-4B04F6D0F872Q40223874-0DE4441C-6165-44D2-A643-F868AA83225FQ40704973-1383257F-BB15-4A18-A04F-F47CBA2AEE2E
P2860
Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Daclizumab versus antithymocyt ...... k renal transplant recipients.
@en
Daclizumab versus antithymocyt ...... k renal transplant recipients.
@nl
type
label
Daclizumab versus antithymocyt ...... k renal transplant recipients.
@en
Daclizumab versus antithymocyt ...... k renal transplant recipients.
@nl
prefLabel
Daclizumab versus antithymocyt ...... k renal transplant recipients.
@en
Daclizumab versus antithymocyt ...... k renal transplant recipients.
@nl
P2093
P2860
P356
P1476
Daclizumab versus antithymocyt ...... k renal transplant recipients.
@en
P2093
Bernard Charpentier
Christian Noël
Dominique Durand
François Bayle
François Berthoux
Georges Mourad
Guy Touchard
Jean-Paul Squifflet
Marc Hazzan
Michèle Kessler
P2860
P304
P356
10.1681/ASN.2008101037
P577
2009-05-21T00:00:00Z